TP53 in AML and MDS: The new (old) kid on the block

Jennifer A Marks¹, Xin Wang², Elena M Fenu³, Adam Bagg⁴, Catherine Lai⁵

Affiliations

¹ Department of Medicine, Division of Hematology and Oncology, Georgetown University, 3800 Reservoir Road NW, Washington, D.C. 20007, USA. Electronic address: jennifer.a.marks@medstar.net.
² Department of Medicine, Division of Hematology and Oncology, Georgetown University, 3800 Reservoir Road NW, Washington, D.C. 20007, USA; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, 12 South Pavilion, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. Electronic address: xin.wang2@pennmedicine.upenn.edu.
³ Department of Pathology and Laboratory Medicine, Division of Hematopathology, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. Electronic address: elena.fenu@pennmedicine.upenn.edu.
⁴ Department of Pathology and Laboratory Medicine, Division of Hematopathology, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. Electronic address: adambagg@pennmedicine.upenn.edu.
⁵ Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, 12 South Pavilion, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. Electronic address: catherine.lai@pennmedicine.upenn.edu.

PMID: 36841672
DOI: 10.1016/j.blre.2023.101055

Review

TP53 in AML and MDS: The new (old) kid on the block

Jennifer A Marks et al. Blood Rev. 2023 Jul.

. 2023 Jul:60:101055.

doi: 10.1016/j.blre.2023.101055. Epub 2023 Feb 14.

Authors

Jennifer A Marks¹, Xin Wang², Elena M Fenu³, Adam Bagg⁴, Catherine Lai⁵

Affiliations

¹ Department of Medicine, Division of Hematology and Oncology, Georgetown University, 3800 Reservoir Road NW, Washington, D.C. 20007, USA. Electronic address: jennifer.a.marks@medstar.net.
² Department of Medicine, Division of Hematology and Oncology, Georgetown University, 3800 Reservoir Road NW, Washington, D.C. 20007, USA; Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, 12 South Pavilion, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. Electronic address: xin.wang2@pennmedicine.upenn.edu.
³ Department of Pathology and Laboratory Medicine, Division of Hematopathology, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. Electronic address: elena.fenu@pennmedicine.upenn.edu.
⁴ Department of Pathology and Laboratory Medicine, Division of Hematopathology, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. Electronic address: adambagg@pennmedicine.upenn.edu.
⁵ Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, 12 South Pavilion, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. Electronic address: catherine.lai@pennmedicine.upenn.edu.

PMID: 36841672
DOI: 10.1016/j.blre.2023.101055

Abstract

MDS and AML are clonal hematopoietic stem cell disorders of increasing incidence, having a variable prognosis based, among others, on co-occurring molecular abnormalities. TP53 mutations are frequently detected in these myeloid neoplasms and portend a poor prognosis with known therapeutic resistance. This article provides a timely review of the complexity of TP53 alterations, providing updates in diagnosis and prognosis based on new 2022 International Consensus Classification (ICC) and World Health Organization (WHO) guidelines. The article addresses optimal testing strategies and reviews current and arising therapeutic approaches. While the treatment landscape for this molecular subgroup is under active development, further exploration is needed to optimize the care of this group of patients with unmet needs.

Trial registration: ClinicalTrials.gov NCT04755244 NCT02663518.

Keywords: Acute myeloid leukemia; International consensus classification; Myelodysplastic syndrome; TP53; World Health Organization.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov
Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

TP53 in AML and MDS: The new (old) kid on the block

Affiliations

TP53 in AML and MDS: The new (old) kid on the block

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous